Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Amarin Corporation plc (ADR) (NASDAQ:AMRN), Abbott Laboratories (NYSE:ABT), St. Jude Medical, Inc. (NYSE:STJ), Gilead Sciences, Inc. (NASDAQ:GILD)
Amarin Corporation plc (ADR) (NASDAQ:AMRN) managed to keep its gain at 4.19% on above-normal volume of 7.65M shares. The stock settled at $7.18 after floating in a range of $6.90 to $7.23. Its latest price has reached market capitalization of $1.24 billion. Its 52-week range has been $5.12 to $12.96. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
For How Long AMRN will fight for Profitability? Read This Trend Analysis report
Abbott Laboratories (NYSE:ABT) traded up on a volume of 7.48 million, lower than its standard daily volume. Shares have gained 0.81% to $33.56. Over the last twelve months, the stock has lost/-2.1% and faced a worst price of $31.64. Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide.
For How Long ABT’s Gloss will Attract Investors? Find out via this report
St. Jude Medical, Inc. (NYSE:STJ) settled 2.63% higher at $56.23 on above-normal volume of 6.63M shares during the last trading day. The stock has its 12-month high at $57.17 and 52-week low price was $30.25. It traded in a range of $55.25 to $57.17 during the last trading day. St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide.
Why Should Investors Buy STJ After the Recent Fall? Just Go Here and Find Out
In the last trading session, Gilead Sciences, Inc. (NASDAQ:GILD) was up on high volume, trading at a volume of 6.35M versus its average daily volume of 6.15 million shares. At $63.04, the stock has attained market capitalization of 96.49 billion. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
Will GILD Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)